Lucie Lovelle is an Associate Director, Science and Technology in the Chemical and Analytical Development organization of Novartis. Lucie earned her PhD in Organic Chemistry from the University of Montreal (Canada), where she worked, under the supervision of Prof. André B. Charette, on the diastereo- and enantioselective synthesis of 1,2,3-trisubstituted cyclopropanes. In 2010, she moved to ETH Zürich (Switzerland) to complete her post-doctoral studies in the group of Prof. Ryan Gilmour, leveraging from the gauche effect to design and synthesize various fluorinated organocatalysts. Lucie was recruited a year later by Janssen, pharmaceutical companies of Johnson & Johnson (Schaffhausen, Switzerland) to work on, among other projects, the development of bedaquiline, an approved marketed drug to treat multi-drug-resistant tuberculosis (MDR-TB). Since 2015, Lucie is working at Novartis in process research & development for drug candidates across indications and phases of clinical development.

Presentation Title: Chemical Development of Remibrutinib

View company profile